688302 Hinova Pharmaceuticals Inc.
- 27.60
- -0.20-0.72%
Hinova Pharmaceuticals Inc. News
Haichuang Pharmaceutical: Voluntary disclosure of the announcement on the completion of the clinical trial of the oral PROTAC drug HP568 tablets in China
Voluntary disclosure announcement on completion of the first clinical trial of the oral PROTAC drug HP568 tablets in China
CITIC Securities Co., Ltd.\'s inspection opinion on the postponement of some fund-raising projects of Haichuang Pharmaceutical Co., Ltd.
Announcement on the postponement of part of the initial public offering of shares
Announcement of Resolutions of the 7th Meeting of the 2nd Board of Supervisors
Haichuang Pharmaceutical Investor Relations Activity Record Form (December 2024)
Haichuang Pharmaceutical: Voluntary disclosure of the US FDA approval of the clinical trial application for oral PROTAC HP568 tablets for the treatment of ER+/HER2-advanced breast cancer
Voluntary disclosure announcement on the US FDA\'s approval of a clinical trial application for oral PROTAC HP568 tablets for the treatment of ER+/HER2-advanced breast cancer
Haichuang Pharmaceutical: Announcement on the plan for shareholders holding 5% or more of the shares to reduce their shareholding
Announcement on plans for shareholders holding 5% or more of the shares to reduce their holdings
Haichuang Pharmaceutical Investor Relations Activity Record Form (November 2024)
Haichuang Pharmaceutical: Announcement on holding a performance briefing for the third quarter of 2024
Announcement on holding the results briefing for the third quarter of 2024
Third Quarter Report 2024
Haichuang Pharmaceutical: Announcement on voluntary disclosure of the clinical trial of the oral PROTAC drug HP568 tablets for the treatment of ER+/HER2-advanced breast cancer to obtain the drug clinical trial approval notice
Notice on voluntary disclosure of the clinical trial of the oral PROTAC drug HP568 tablets for the treatment of ER+/HER2-advanced breast cancer to obtain the drug clinical trial approval notice
Announcement on the expiration of the holdings reduction plan for shareholders holding 5% or more of the shares and the change in equity of 1%
Haichuang Pharmaceutical Investor Relations Activity Record Form (September 2024)
Voluntary disclosure announcement on the approval of the US FDA for clinical trial application of HP515 tablets for the treatment of metabolic steatohepatitis (MASH)
CITIC Securities Co., Ltd.\'s 2024 semi-annual continuous supervision and follow-up report on Haichuang Pharmaceutical Co., Ltd.
No Data